
LY450108
CAS No. 376594-67-1
LY450108( —— )
Catalog No. M29625 CAS No. 376594-67-1
LY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 160 | Get Quote |
![]() ![]() |
10MG | 260 | Get Quote |
![]() ![]() |
25MG | 465 | Get Quote |
![]() ![]() |
50MG | 673 | Get Quote |
![]() ![]() |
100MG | 945 | Get Quote |
![]() ![]() |
500MG | 1881 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameLY450108
-
NoteResearch use only, not for human use.
-
Brief DescriptionLY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.
-
DescriptionLY450108 is a potentiator of the AMPA receptor that can be used in Parkinson's disease studies.
-
In VitroAMPA receptors mediate most of the excitatory neurotransmission and play a key role in synaptic plasticity in the mammalian central nervous system (CNS). Recent evidence has shown that in addition to modulating fast synaptic plasticity and memory processes, AMPA receptor potentiators alter downstream signalling pathways and may thereby have utility in other CNS disorders.
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetiGluR
-
RecptoriGluR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number376594-67-1
-
Formula Weight396.45
-
Molecular FormulaC19H22F2N2O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 50 mg/mL (126.12 mM)
-
SMILESCC(C)S(NC[C@H](C)c(cc1)ccc1NC(c1cc(F)cc(F)c1)=O)(=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
JNJ-61432059
JNJ-61432059 is an oral active and selective negative modulator of TARP γ?8 Selective AMPAR(pIC50: 9.7).
-
L-701324
A potent, orally active antagonist at the glycine modulatory site on NMDA receptor with IC50 of 2 nM.
-
UK-240455
UK-240455 is a potent and selective N-methyl-D-aspartic acid (NMDA) glycine receptor antagonist with neuroprotective effects and improvements in motor function in Parkinson's disease models, making it a potential candidate for Parkinson's disease treatment.